Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in atopic dermatitis (also known as eczema).
Belgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis drugs, where the big US pharma will pay $3.95 billion up front and
Shares in the Belgian biotech Galapagos have surged after a late stage trial of filgotinib, a rheumatoid arthritis drug it is developing with Gilead, met all its endpoints.
Swiss pharma Novartis is to pay up to $1 billion to Galapagos and MorphoSys for exclusive rights to a skin drug, which will further strengthen Novartis’s leadership position in the immunolo
